We’re excited to share our latest manuscript “Real-world Utilization of Biologic and targeted Synthetic Disease- Modifying Anti- Rheumatic Drugs in Psoriatic Arthritis and Axial Spondyloarthritis : Insights from Sweden and Germany”” now available online in 𝘈𝘥𝘷𝘢𝘯𝘤𝘦𝘴 𝘪𝘯 𝘛𝘩𝘦𝘳𝘢𝘱𝘺, co‑authored by Quantify’s Alexandra Cooper and alumni Alexander Rieem Dun and Christoph Abé.
Coordinated and executed by Quantify Research on behalf of UCB, this study sought to characterize patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) initiating biologic or targeted synthetic disease‑modifying anti‑rheumatic drugs (b/tsDMARDs), using Swedish national administrative health registries (2017–2021) and German regional insurance claims data (2018–2021).
𝐓𝐡𝐞 𝐬𝐭𝐮𝐝𝐲 𝐟𝐨𝐮𝐧𝐝 𝐭𝐡𝐚𝐭:
🟢 Patients with PsA were generally older and more often female than those with axSpA at b/tsDMARD initiation.
🟢 Most patients had prior NSAID and corticosteroid use at the time of b/tsDMARD initiation.
🟢 Among patients newly initiating a b/tsDMARD during the identification period, the most common initial mode of action was anti‑TNF.
🟢 German patients more often received higher maintenance doses of secukinumab, ixekizumab, and guselkumab compared to Swedish patients.
👉 These insights highlight the value of RWD for characterizing patient profiles and supporting tailored, patient‑centered treatment strategies for PsA and axSpA.
📖 Read the full article here:
💬 Looking for an expert provider of European RWE in with extensive experience in dermatology and rheumatology? Get in touch!